# A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).

> **NCT00405080** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 12 (actual)

## Conditions studied

- Nausea and Vomiting, Chemotherapy-Induced

## Interventions

- **DRUG:** GW679769 (Casopitant) oral tablets
- **DRUG:** Rifampin oral capsules

## Key facts

- **NCT ID:** NCT00405080
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11-11
- **Primary completion:** 2007-01-05
- **Final completion:** 2007-01-05
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00405080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00405080, "A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT00405080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*